{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:20:57Z","timestamp":1790785257851,"version":"4.1.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":74,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-56539-w","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T20:54:47Z","timestamp":1780692887000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative detection of macrophage activation in osteosarcoma comparing 18F-FDG PET\/CT with ferumoxytol-enhanced MRI"],"prefix":"10.1038","volume":"16","author":[{"given":"Raheleh","family":"Roudi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frezghi","family":"Habte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Marco","family":"Saladino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iryna","family":"Vasyliv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike E.","family":"Daldrup-Link","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"56539_CR1","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1186\/s12885-025-13496-3","volume":"25","author":"R Boyland","year":"2025","unstructured":"Boyland, R. et al. Comparison of overall survival of adult and pediatric osteosarcoma patients using the national cancer database. BMC Cancer 25, 290 (2025).","journal-title":"BMC Cancer"},{"key":"56539_CR2","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1002\/1878-0261.12556","volume":"13","author":"S Mohanty","year":"2019","unstructured":"Mohanty, S., Aghighi, M., Yerneni, K., Theruvath, J. L. & Daldrup-Link, H. E. Improving the efficacy of osteosarcoma therapy: Combining drugs that turn cancer cell \u2018don\u2019t eat me\u2019 signals off and \u2018eat me\u2019 signals on. Mol. Oncol. 13, 2049\u20132061 (2019).","journal-title":"Mol. Oncol."},{"key":"56539_CR3","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.3390\/cells13221862","volume":"13","author":"Y Ko","year":"2024","unstructured":"Ko, Y. et al. CD47 in osteosarcoma: Correlation with metastasis and macrophage-mediated phagocytosis. Cells 13, 1862 (2024).","journal-title":"Cells"},{"key":"56539_CR4","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1148\/radiol.2018181204","volume":"290","author":"M Iv","year":"2019","unstructured":"Iv, M. et al. Quantification of macrophages in high-grade gliomas by using Ferumoxytol-enhanced MRI: A pilot study. Radiology 290, 198\u2013206 (2019).","journal-title":"Radiology"},{"key":"56539_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1148\/radiol.2019190477","volume":"564","author":"KL Nguyen","year":"2019","unstructured":"Nguyen, et al. Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI. Radiology 564, 554\u2013564 (2019).","journal-title":"Radiology"},{"issue":"2","key":"56539_CR6","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41419-018-1285-3","volume":"36","author":"S Mohanty","year":"2019","unstructured":"Mohanty, et al. Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma. Cell Death Dis. 3636. (2019).","journal-title":"Cell Death Dis."},{"key":"56539_CR7","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.2967\/jnumed.122.265278","volume":"1377","author":"U Metser","year":"2023","unstructured":"Metser, U. [18F]FDG PET\/CT in the Initial Staging and Restaging of Soft-Tissue or Bone Sarcoma in Patients with Negative or Equivocal Findings for Metastases or Limited Recurrence on Conventional Work-up: Results of a Prospective Multicenter Registry. J. Nucl. Med. 1377, 1371\u20131377 (2023).","journal-title":"J. Nucl. Med."},{"key":"56539_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-019-0588-4","author":"I Lee","year":"2020","unstructured":"Lee, et al. Early response monitoring of neoadjuvant chemotherapy using [18F]FDG PET can predict the clinical outcome of extremity osteosarcoma. EJNMMI Res. https:\/\/doi.org\/10.1186\/s13550-019-0588-4 (2020).","journal-title":"EJNMMI Res."},{"key":"56539_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.10.775","volume":"35","author":"T Takemori","year":"2024","unstructured":"Takemori, T. et al. 742P 18F-FDG PET\/CT can stratify the prognosis of standard responders after neoadjuvant chemotherapy in osteosarcoma. Ann. Oncol. 35, S1680 (2024).","journal-title":"Ann. Oncol."},{"key":"56539_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-15964-3","volume":"12","author":"O Yamaguchi","year":"2022","unstructured":"Yamaguchi, O. et al. Prospective assessment using 18F-FDG PET\/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer. Sci. Rep. 12, 11832 (2022).","journal-title":"Sci. Rep."},{"key":"56539_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1111\/1754-9485.70066","volume":"70","author":"P Macilwraith","year":"2026","unstructured":"Macilwraith, P. et al. Incidence of reported pseudoprogression on 18F-FDG PET\/CT in metastatic melanoma patients undergoing immune checkpoint inhibitor immunotherapy. J. Med. Imaging Radiat. Oncol. 70, 162\u2013168 (2026).","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"56539_CR12","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1111\/1754-9485.13390","volume":"66","author":"MH Cherk","year":"2022","unstructured":"Cherk, M. H. et al. 18 F-FDG PET\/CT features of immune-related adverse events and pitfalls following immunotherapy. J. Med. Imaging Radiat. Oncol. 66, 483\u2013494 (2022).","journal-title":"J. Med. Imaging Radiat. Oncol."},{"key":"56539_CR13","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1023\/A:1006767007547","volume":"18","author":"C Khanna","year":"2000","unstructured":"Khanna, C. et al. An orthotopic model of murine osteosarcoma with clonally related variants differing in pulmonary metastatic potential. Clin. Exp. Metastasis 18, 261\u2013271 (2000).","journal-title":"Clin. Exp. Metastasis"},{"key":"56539_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/RLI.0000000000001030","author":"R Roudi","year":"2023","unstructured":"Roudi, R., Pisani, L., Pisani, F., Kiru, L. & Daldrup-Link, H. E. Novel Clinically Translatable Iron Oxide Nanoparticle for Monitoring Anti-CD47 Cancer Immunotherapy. Invest. Radiol. https:\/\/doi.org\/10.1097\/RLI.0000000000001030 (2023).","journal-title":"Invest. Radiol."},{"key":"56539_CR15","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/s41596-024-00998-w","volume":"19","author":"SI De Vleeschauwer","year":"2024","unstructured":"De Vleeschauwer, S. I. et al. OBSERVE: guidelines for the refinement of rodent cancer models. Nat. Protoc. 19, 2571\u20132596 (2024).","journal-title":"Nat. Protoc."},{"key":"56539_CR16","doi-asserted-by":"publisher","DOI":"10.3791\/64773","author":"SK Ramasamy","year":"2023","unstructured":"Ramasamy, S. K. et al. Measurement of Tumor T2* Relaxation Times after Iron Oxide Nanoparticle Administration. J. Vis. Exp. https:\/\/doi.org\/10.3791\/64773 (2023).","journal-title":"J. Vis. Exp."},{"key":"56539_CR17","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","volume":"9","author":"J Schindelin","year":"2012","unstructured":"Schindelin, J., Arganda-Carreras, I. & Frise, E. Fiji: an open-sourceplatform for biological-image analysis. Nat. Methods 9, 676\u2013682 (2012).","journal-title":"Nat. Methods"},{"key":"56539_CR18","doi-asserted-by":"publisher","first-page":"4671","DOI":"10.1158\/1078-0432.CCR-17-0114","volume":"23","author":"M Nishino","year":"2017","unstructured":"Nishino, M. et al. Immune-related tumor response dynamics in melanoma patients treated with pembrolizumab: Identifying markers for clinical outcome and treatment decisions. Clin. Cancer Res. 23, 4671\u20134679 (2017).","journal-title":"Clin. Cancer Res."},{"key":"56539_CR19","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.1002\/cam4.2797","volume":"2652","author":"P Martin-Romano","year":"2020","unstructured":"Martin-Romano, et al. Evidence of pseudoprogression in patients treated with PD1\/PDL1 antibodies across tumor types. Cancer Med. 2652, 2643\u20132652 (2020).","journal-title":"Cancer Med."},{"key":"56539_CR20","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.32604\/or.2025.071708","volume":"33","author":"X Guo","year":"2025","unstructured":"Guo, X., Fu, Y., Baran, N. & Ma, W. CD47-targeted therapy in cancer immunotherapy: At a crossroads of promise and challenge. Oncol. Res. 33, 3375\u20133385 (2025).","journal-title":"Oncol. Res."},{"key":"56539_CR21","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1016\/j.athoracsur.2019.10.061","volume":"1025","author":"KH Kernstine","year":"2020","unstructured":"Kernstine, et al. Does tumor FDG-PET avidity represent enhanced glycolytic metabolism in non-small cell lung cancer?. Ann. Thorac. Surg. 1025, 1019\u20131025 (2020).","journal-title":"Ann. Thorac. Surg."},{"key":"56539_CR22","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1007\/s11307-022-01776-4","volume":"25","author":"EJ de Koster","year":"2023","unstructured":"de Koster, E. J. et al. [18F]FDG uptake and expression of immunohistochemical markers related to glycolysis, hypoxia, and proliferation in indeterminate thyroid nodules. Mol. Imaging Biol. 25, 483\u2013494 (2023).","journal-title":"Mol. Imaging Biol."},{"key":"56539_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50104-7","volume":"6438","author":"M Wang","year":"2024","unstructured":"Wang, et al. Phosphorylation of PFKL regulates metabolic reprogramming in macrophages following pattern recognition receptor activation. Nat. Commun. 6438, 6438 (2024).","journal-title":"Nat. Commun."},{"key":"56539_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.618705","volume":"618705","author":"YS An","year":"2021","unstructured":"An, et al. Correlation between 18F-FDG uptake and immune cell infiltration in metastatic brain lesions. Front. Oncol. 618705, 618705 (2021).","journal-title":"Front. Oncol."},{"key":"56539_CR25","doi-asserted-by":"publisher","first-page":"e502","DOI":"10.1016\/j.crad.2023.02.009","volume":"78","author":"L-J Li","year":"2023","unstructured":"Li, L.-J., Xuan, J.-Z. & Zheng, H.-N. Correlation of 18F-FDG PET\/CT metabolic parameters with the expression of immune biomarkers in the tumour microenvironment in lung adenocarcinoma. Clin. Radiol. 78, e502\u2013e509 (2023).","journal-title":"Clin. Radiol."},{"key":"56539_CR26","doi-asserted-by":"publisher","first-page":"2190","DOI":"10.1158\/1078-0432.CCR-20-3706","volume":"2199","author":"SM Ansell","year":"2021","unstructured":"Ansell, et al. Phase I study of the CD47 blocker TTI-621 in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2199, 2190\u20132199 (2021).","journal-title":"Clin. Cancer Res."},{"key":"56539_CR27","doi-asserted-by":"publisher","first-page":"3996","DOI":"10.1158\/1078-0432.CCR-24-0103","volume":"30","author":"H Gelderblom","year":"2024","unstructured":"Gelderblom, H. et al. CSF1R inhibition in patients with advanced solid tumors or tenosynovial giant cell tumor: A phase I study of vimseltinib. Clin. Cancer Res. 30, 3996\u20134004 (2024).","journal-title":"Clin. Cancer Res."},{"key":"56539_CR28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1002\/ijc.32141","volume":"1199","author":"SMM Irenaeus","year":"2019","unstructured":"Irenaeus, et al. First-in-human study with intratumoral administration of a CD40 agonistic antibody, ADC-1013, in advanced solid malignancies. Int. J. Cancer 1199, 1189\u20131199 (2019).","journal-title":"Int. J. Cancer"},{"key":"56539_CR29","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1159\/000505651","volume":"29","author":"MH Younis","year":"2020","unstructured":"Younis, M. H., Abu-Hijleh, H. A., Aldahamsheh, O. O., Abualruz, A. & Thalib, L. Meta-analysis of the diagnostic accuracy of primary bone and soft tissue sarcomas by 18F-FDG-PET. Med. Princ. Pract. 29, 465\u2013472 (2020).","journal-title":"Med. Princ. Pract."},{"key":"56539_CR30","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.2967\/jnumed.122.265247","volume":"1525","author":"NL Albert","year":"2023","unstructured":"Albert, et al. Prognostic value of TSPO PET before radiotherapy in newly diagnosed IDH-wild-type glioblastoma. J. Nucl. Med. 1525, 1519\u20131525 (2023).","journal-title":"J. Nucl. Med."},{"key":"56539_CR31","doi-asserted-by":"crossref","first-page":"e2761","DOI":"10.1212\/WNL.0000000000012033","volume":"96","author":"J Van Den Ameele","year":"2021","unstructured":"Van Den Ameele, J. et al. 11C]PK11195-PET Brain Imaging of the Mitochondrial Translocator Protein in Mitochondrial Disease. Neurology 96, e2761 (2021).","journal-title":"Neurology"},{"key":"56539_CR32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2409668121","volume":"121","author":"Y Lauwers","year":"2024","unstructured":"Lauwers, et al. Imaging of tumor-associated macrophage dynamics during immunotherapy using a CD163-specific nanobody-based immunotracer. Proc. Natl. Acad. Sci. U. S. A. 121, e2409668121 (2024).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"56539_CR33","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1021\/acs.molpharmaceut.3c00311","volume":"20","author":"C Liang","year":"2023","unstructured":"Liang, C. et al. ImmunoPET imaging of CD47 with VHH-derived tracers in pancreatic cancers. Mol. Pharm. 20, 4184\u20134195 (2023).","journal-title":"Mol. Pharm."},{"key":"56539_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1264179","volume":"14","author":"TR Wagner","year":"2023","unstructured":"Wagner, T. R. et al. Two birds with one stone: Human SIRP\u03b1 nanobodies for functional modulation and in vivo imaging of myeloid cells. Front. Immunol. 14, 1264179 (2023).","journal-title":"Front. Immunol."},{"key":"56539_CR35","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1021\/acsptsci.3c00303","volume":"7","author":"X Zhang","year":"2024","unstructured":"Zhang, X. et al. Chemokine receptor 2 targeted PET\/CT imaging distant metastases in pancreatic ductal adenocarcinoma. ACS Pharmacol. Transl. Sci. 7, 285\u2013293 (2024).","journal-title":"ACS Pharmacol. Transl. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56539-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56539-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56539-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:02:42Z","timestamp":1787007762000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-56539-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["56539"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-56539-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were approved by the Stanford University Administrative Panel on Laboratory Animal Care (Protocol 24965).","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"25762"}}